Trial · NCT06747845
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
NCT06747845, Phase 2, Recruiting, Abramson Cancer Center at Penn Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy. Trials, record NCT06747845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06747845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
- NCT number
- NCT06747845
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- Niraparib, FOLFIRI, Ipilimumab
- First posted
- 2024-12-24
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) in the experimental arm | From Cycle 1 (each cycle in Arm A is 21 days) Day 1 to disease progression, loss to follow-up or death from any cause, whichever came first, assessed up to 42 months. | PFS is defined as the time from randomization to the occurrence of disease progression according to RECIST v1.1, as assessed by the investigator, or death from any cause. Median PFS and 95% confidence interval will be estimated from the Kaplan-Meier curve. In the primary outcome measure, PFS will be assessed in Arm A. |
| Secondary | Overall response rate (ORR) in the experimental arm | From first restaging assessment through completion of study treatment (maximum 42 months) | The proportion of patients who achieve a complete or partial response, as determined by RECIST v1.1, in Arm A |
| Secondary | Overall survival (OS) in the experimental arm | From Cycle 1 (each cycle in Arm A is 21 days) Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first | Time from randomization to death from any cause in Arm A |
| Secondary | Disease Control in the experimental arm | From Cycle 1 (each cycle in Arm A is 21 days) Day 1 to disease progression, loss to follow-up or death from any cause, whichever came first, assessed up to 42 months.. | Achieving stable disease (SD), partial response (PR), or complete response (CR) per RECIST v1.1, in Arm A |
| Secondary | Safety and tolerability of Niraparib plus Ipilimumab in the experimental arm | From Cycle 1 (each cycle in Arm A is 21 days) Day 1 through 90 days after patient End of Treatment Visit | The incidence of adverse events (AEs), clinical laboratory abnormalities and dose modifications, as determined by CTCAE v5.0, in Arm A |
| Secondary | PFS in the control arm | From Cycle 1 (each cycle in Arm B is 28 days) Day 1 to disease progression, loss to follow-up or death from any cause, whichever came first, assessed up to 42 months. | PFS is defined as the time from randomization to the occurrence of disease progression according to RECIST v1.1, as assessed by the investigator, or death from any cause. Median PFS and 95% confidence interval will be estimated from the Kaplan-Meier curve. In the secondary outcome measure, PFS will be assessed in Arm B. |
| Secondary | OS in the control arm | From Cycle 1 (each cycle in Arm B is 28 days) Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first | Time from randomization until death from any cause or last follow-up in Arm B |
| Secondary | Overall response in evaluable patients within the control arm | From first restaging assessment through completion of study treatment (maximum 42 months) | The proportion of patients who achieve a complete or partial response, as determined by RECIST v1.1, in Arm B |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06747845
GET https://conductscience.org/api/trials/v1/NCT06747845/registered